Atrogi's breakthrough discovery enables chronic use of next-generation, highly selective β2-agonists for the first time in metabolic diseaseFirst-in-class oral therapy ATR-258 mimics the effects...
Atrogi's breakthrough discovery enables chronic use of next-generation, highly selective β2-agonists for the first time in metabolic diseaseFirst-in-class oral therapy ATR-258 mimics the effects...
Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation